Global Parasitic Diseases Therapeutics Market Report and Forecast 2024-2032

Global Parasitic Diseases Therapeutics Market Outlook

The global parasitic diseases therapeutics market size was valued at USD 1.79 billion in 2023. Rising disposable incomes, increasing population, and the rising prevalence of parasites are the driving factors of this market. The market is anticipated to grow at a CAGR of 5% during the forecast period 2024-2032 to reach a value of USD 2.77 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Segmentation

Amebiasis, African sleeping disease, trichomoniasis, giardiasis, trypanosomiasis, leishmaniasis, and malaria are all parasitic diseases that need treatment. Based on the product, the parasitic diseases therapeutics market can be divided into:

• Antiprotozoal Therapeutics
• Anthelminthic Therapeutics
• Scabicides And Pediculicides Therapeutics

The EMR report looks into the regional parasitic diseases therapeutics markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

Protozoal, along with helminthic worm diseases, have raised the mortality and morbidity of prophylactic therapy. Preventive chemotherapy is used to monitor the spread within a population of helminthic infections. The high prevalence of malaria worldwide prompted researchers to develop different vaccines to prevent the disease from spreading. Researchers are also developing a variety of prophylactic vaccines to treat and prevent skin leishmaniasis and visceral leishmaniasis. The growing acceptance of these prophylactic vaccines for the prevention and control of parasite diseases is one of the key market developments on parasitic diseases, which would have a positive effect on the market growth.

The occurrence of protozoan, helminth, as well as ectoparasite infections, is rapidly rising. The number of individuals infected with whipworms and hookworms is increasing annually. The number of cases of African trypanosomiasis recorded has also increased considerably, particularly in countries in sub-Saharan Africa like Zambia, Tanzania, Uganda, and Malawi. Likewise, in parts of Central America, South America, and Mexico, the prevalence of Chagas disease is high. In addition, the prevalence of schistosomiasis is also rising globally. The increasing prevalence of these parasites will lead to a growing demand for the treatment of parasites. The antiprotozoal therapeutics segment accounted for the largest market share in 2020.

However, the challenges related to the discovery of antiparasitic drugs and disease diagnosis, increased drug resistance, lack of effective therapies, and side-effects may impede the development of the parasite diseases therapeutics industry in the coming years.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

The report presents a detailed analysis of the following key players in the global parasitic diseases therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• F. Hoffmann-La Roche
• Novartis AG
• GlaxoSmithKline PLC
• Sanofi SA
• Pfizer Inc.
• Others

The EMR report gives an in-depth insight into the parasitic diseases therapeutics market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report